COVID-19 Vaccine Manufacturer Selects Innovative Cleanroom Insulation Technology Benefits for Condensation Control

Shenzhen Kangtai is a leading player in the research, development, production and sale of biological products, and is one of the largest Chinese manufacturers of recombinant hepatitis B vaccines. The company plays an important role in China’s national plan for immunization, having produced and sold over one billion doses of hepatitis B vaccine alone.

Shenzhen Kangtai is also involved in numerous key national, provincial and municipal research projects and technology developments. The company’s R&D program includes COVID-19 vaccines, including exploring a number of technical routes, such as the COVID-19 inactivated vaccine (Vero cell) and the adenovirus vector COVID-19 vaccine. The first phase of the COVID-19 inactivated vaccine production workshop in Shenzen’s Nanshan District has been completed and is expected to have an annual capacity of 100 million doses.

Improving Environmental Performance

A review of the cleanroom environment was part of the program, and this identified several areas where insulation could be improved. These included replacing the existing rubber insulation, giving more complete coverage in parts of the pipework where space was tight and reducing time and effort to maintain the most stringent levels of cleanliness.

A closed cell clean technology insulation product designed and manufactured specifically for use in cleanrooms increased long-term cost-effectiveness and helped eliminate risk within their facilities.